A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew

H Cuppens, P Marynen, C De Boeck, F De Baets, E Eggermont, H Van den Berghe, J J Cassiman

Abstract
The clinical and molecular findings in an infant with mild manifestations of cystic fibrosis, who is homozygous for the G542X mutation, and her heterozygous nephew, who is severely affected, are described.

The major mutation recently identified in the CFTR gene1-3 is a specific deletion of three base pairs, which results in the loss of a phenylalanine residue at amino acid position 508 (ΔF508). In a sample of Belgian CF patients, 68.1% of all CF chromosomes (94 out of 138 CF chromosomes) carried this mutation.

Since then, a series of rarer mutations has been reported (CF genetic analysis consortium, personal communication), including the 2566insAT5 and the G542X mutation (Kerem et al, personal communication). The 2566insAT mutation was not present in our Belgian population sample. In our CF patients, the G542X mutation, in which the glycine (GGA) at amino acid position 542 in exon 11 is mutated to a stop codon (TGA), accounted for 7.3% of the CF chromosomes, being probably the second most frequent CF mutation in this population sample.

Here we describe the clinical and molecular findings in a child who is only mildly affected although homozygous for the mutation, and a child who is severely affected and heterozygous for the G542X mutation and a new mutation in exon 9 (G458V).

Case report
II.1 (fig 1) is the oldest of three sibs born to healthy, unrelated, Belgian parents. The diagnosis of cystic fibrosis was made by a positive sweat chloride test at the age of 3 years, after the diagnosis in his younger niece (II.2). Initially the gastrointestinal problems, especially malabsorption, were more pronounced than the respiratory symptoms.

By the age of 9 years the respiratory insufficiency was pronounced (pH 7.44, Pco₂ 52 mmHg, Po₂ 48 mmHg, Hco₃ 35, basic excess +10) and he showed signs of cor pulmonale on ECG and electrocardiography. Sputum cultures grew Pseudomonas.

Pulmonary function test showed a total lung capacity 112.5% of normal, vital capacity 24%, functional residual capacity 194%, and residual volume 358% of normal. The child died at the age of 12 years of respiratory insufficiency and right heart failure.

II.2 is the oldest of three sibs born to healthy, unrelated, Belgian parents. She was diagnosed as having cystic fibrosis at the age of 2 years because of a history of failure to gain weight in the presence of
copious fatty stools, rectal prolapse, and a positive pilocarpine sweat chloride test. Once treatment with pancreatic enzyme supplements, vitamin supplements, and daily chest physiotherapy was instituted, she thrived well. Intermittent cough and daily sputum production owing to respiratory tract disease started at the age of 5 years. *Staphylococcus aureus* or *Haemophilus influenzae* or both were found in the sputum throughout childhood. *Pseudomonas aeruginosa* was recovered from the sputum from the age of 10 years onwards. She was admitted to hospital at the age of 11 1/2 years because of fever, cough, increased sputum production, and weight loss of several weeks duration. Chest x-ray showed hyperinflation as well as inhomogeneous infiltrates in the lingula and right middle lobe. Sputum culture grew 2+ *Pseudomonas aeruginosa* resistant to tobramycin and piperacillin. Ceftazidim was administered intravenously for 14 days and the girl recovered well. The pulmonary infiltrates resolved completely. At present she is 12 1/2 years old and she continues to do very well. She is very active in sport. She produces a moderate amount of yellowish sputum a day (about 10). She has two or three bowel movements a day and no abdominal complaints. Her height is 160 cm and weight is 51.4 kg, both between the 75th and 97th centile. Physical examination is normal and there is no obvious hyperinflation, normal lung auscultation, and no abdominal distension or hepatosplenomegaly. Tanner pubertal score is M2P2A2. Sputum culture consistently grows *Pseudomonas aeruginosa*. Pulmonary function tests are excellent: vital capacity 117% of normal, forced expiratory volume in one second 120% of normal, Tiffeneau index 85, thoracic gas volume 117%, as well as normal flow rates at low lung volumes and normal airway resistance. Chest x-ray shows mild hyperinflation and mild increase in bronchovascular markings. Shwachman score is 90/100.

Genomic DNA extracted from peripheral blood of all members of the family was amplified by PCR with the 11i5, 11i3 primers and 9i5, 9i3 primers (Zielenski and Tsui, personal communication). Amplified DNA was dot blotted on Zetaprobe. The membranes were hybridised with 32P labelled oligonucleotide probes: for the G542 exon (G542X: 5'-CAT GGA CAC AAC TCA TTC AAG AAC T-3'; control: 5'-ACC TTC TCC AAG AAC T-3') and for the G458 exon (G458X: 5'-GT TGT GCT GTA TCC ACT G-3'; control: 5'-GT TGT GCT GGA TCC ACT G-3').

The membranes were washed in stringent conditions (10 mins at 42°C in 6×SSC, 0.1% SDS; 2×30 mins at 45°C in 2×SSC for the control and G542X, 10 mins at 42°C in 6×SSC, 0.1% SDS; 2×30 mins at 56°C in 2×SSC for the control of exon G458, 10 mins at 42°C in 6×SSC, 0.1% SDS; 2×30 mins at 52°C in 2×SSC for G458) and autoradiographed for three hours at −70°C.

Sequence of the fragment containing exon 9 was done with the T7 sequencing™ kit (Pharmacia) according to the following modified protocol. The amplified fragments were purified with GeneClean (Bio101) and were mixed with 15 ng of an internal end labelled primer (5'-CAT GGA CACCAA ATT AAC TTC-3'). The fragments were denatured for three minutes at 100°C and cooled on ice. Annealing buffer, labelling mix, dATP, and T7 DNA polymerase were added together, mixed, and the total reaction mixture was immediately split into four tubes containing the dideoxymixes (short). The sequencing reactions were kept for five minutes at room temperature, then for

![Figure 2](http://jmg.bmj.com/)

**Figure 2** Detection of the mutation G458V by direct sequencing of exon 9. To allow for direct comparison, the termination reactions for each nucleotide (respectively dA, dT, dG, and dC) of the different samples were loaded in adjacent lanes. Lane 1 control, lane 2 II.1, and lane 3 II.2. The mutation (C→A) is indicated by an arrow.
five minutes at 37°C and stop solution was added. The sequencing reaction products were then separated on a 6% acrylamide/8 mol/l urea gel. The gel was fixed in 10% acetic acid/10% methanol solution, dried, and exposed.

Dot blot analysis (fig 1) showed that the CF girl (II.2) was homozygous and her cousin (II.1) heterozygous for the G542X mutation. Direct sequencing of an amplified fragment, containing exon 9, of patient II.1 detected a new mutation (fig 2), resulting in a substitution of a conserved glycine (GGA) for a valine (GTA) at amino acid position 458 (G458V). This was confirmed by dot blot analysis (fig 1). This mutation segregates with the haplotype 2 1 1 1 (XV2c, CS7, KM19, D9). This amino acid substitution is most likely a disease mutation rather than a polymorphism because glycine is a very conserved amino acid in the nucleotide binding fold of this region and this substitution was not detected in 45 normal chromosomes, 20 of them with the same haplotype 2 1 1 1 (XV2c, CS7, KM19, D9). This mutation has been found in one out of 31 CF chromosomes, which carry a so far unknown mutation. Three other CF chromosomes with this haplotype did not carry this mutation and therefore at least one other mutation might be associated with this haplotype. This mutation has not been found in 21 ΔF508 chromosomes, one ΔI507 chromosome (CF genetic analysis consortium), or in two G542X chromosomes.

The G542X mutation segregates with the haplotype 1 2 2 2 (XV2c, CS7, KM19, D9) and was found in 10 out of 41 non-ΔF508, non-ΔI507 CF chromosomes. Since 68.1% of all CF chromosomes carry the ΔF508 deletion in our population sample, the G542X mutation accounts for 7.3% (10 out of 138 CF chromosomes) and the G458V mutation accounts for less than 1% (one out of 138 CF chromosomes) of all the CF chromosomes in this sample.

Based on the quite mild clinical picture, one would have expected that the CF girl carried a mutation in a non-essential part of the gene. The G542X mutation, however, creates a stop codon at amino acid 542. Therefore, only the first 541 codons, out of 1480 codons, would be translated, resulting in a CFTR protein composed of the first membrane spanning segment and half of the first putative nucleotide binding fold (including only two out of the three very conserved regions). Splicing events, which would jump this mutation and allow the synthesis of an almost normal protein, cannot be ruled out, however.

In contrast, the nephew who was homozygous for the G458V mutation and shares the G542X mutation with II.2, suffered from an apparently severe form of CF. This would suggest the G458V mutation might be a rather severe mutation.

Experiments directed towards examination of the CFTR mRNA of the homozygous G542X patient (II.2) and protein analysis using antibodies to different domains of the CF protein will allow the study of the exact structure of the synthesised proteins and their insertion as ‘truncated’ molecule, as dimer, or as alternatively spliced protein in the cell membrane, while patch clamp studies should allow one to evaluate the functional properties of the protein. This may be helpful in the analysis of structure-function relations of the CFTR protein and provide some insight into the complexity of the pathophysiology of CF.

The authors are grateful for the generous collaboration of the family members described here. The technical assistance of Marielle Braeken and Katrien Van den Bosch is gratefully acknowledged. This work was supported by the Inter-University Network for Fundamental Research sponsored by the Belgian Government (1987–1991).

A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew

H Cuppens, P Marynen, H Van den Berghe, J J Cassiman, C De Boeck, E Eggermont and F De Baets

doi: 10.1136/jmg.27.11.717

Updated information and services can be found at:
http://jmg.bmj.com/content/27/11/717

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/